{"id":6926,"date":"2018-03-22T16:28:10","date_gmt":"2018-03-22T16:28:10","guid":{"rendered":"https:\/\/oncopeptides.com\/investors\/aktien\/nyemissioner\/nyemission-mars-2018\/"},"modified":"2026-03-19T15:55:08","modified_gmt":"2026-03-19T15:55:08","slug":"nyemission-mars-2018","status":"publish","type":"investors","link":"https:\/\/oncopeptides.com\/sv\/investerare\/aktien\/nyemissioner\/nyemission-mars-2018\/","title":{"rendered":"Nyemission mars 2018"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6926\" class=\"elementor elementor-6926 elementor-6851\" data-elementor-post-type=\"investors\">\n\t\t\t\t<style>\n                .elementor-element-26156b5{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-26156b5 e-flex e-con-boxed e-con e-parent\" data-id=\"26156b5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<style>\n                .elementor-element-fd2fe76{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-fd2fe76 e-con-full haus-2-1 e-flex e-con e-child\" data-id=\"fd2fe76\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a86f586 elementor-widget elementor-widget-heading\" data-id=\"a86f586\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Nyemission<br><span style=\"color: var(--color-orange)\">Mars 2018<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-394da30 dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"394da30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-7fc1ea1{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-7fc1ea1 e-con-full e-flex e-con e-child\" data-id=\"7fc1ea1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a282ef4 elementor-widget elementor-widget-text-editor\" data-id=\"a282ef4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides har genomf\u00f6rt en riktad nyemission om cirka 314 miljoner kronor<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8e124f0 elementor-widget elementor-widget-text-editor\" data-id=\"8e124f0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>22 mars 2018 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB offentligg\u00f6r idag att Bolaget framg\u00e5ngsrikt har genomf\u00f6rt en riktad nyemission om cirka 314 miljoner kronor (USD 38 miljoner).<\/p><p>Styrelsen f\u00f6r Oncopeptides har, med st\u00f6d av emissionsbemyndigandet fr\u00e5n \u00e5rsst\u00e4mman den 18 maj 2017, och i enlighet med vad som indikerades i Bolagets pressmeddelande den 21 mars 2018, beslutat om en riktad nyemission av 3 980 000 aktier till en teckningskurs om 79 kronor per aktie (\u201dNyemissionen\u201d), vilket inneb\u00e4r att Bolaget kommer att tillf\u00f6ras en bruttolikvid om cirka 314 miljoner kronor.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a8478d7 elementor-widget elementor-widget-button\" data-id=\"a8478d7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-har-genomfort-en-riktad-nyemission-om-cirka-1-106-miljoner-kronor-130-miljoner-usd\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2cdf78b dotted-divider elementor-widget-divider--view-line elementor-widget elementor-widget-divider\" data-id=\"2cdf78b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"divider.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-divider\">\n\t\t\t<span class=\"elementor-divider-separator\">\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t<style>\n                .elementor-element-e67efb4{\n                --padding-top: var(--webien-padding-top-none);\n                --padding-right: var(--webien-padding-right-none);\n                --padding-bottom: var(--webien-padding-bottom-none);\n                --padding-left: var(--webien-padding-left-none);\n                }\n            <\/style><div class=\"webien-container-padding-none elementor-element elementor-element-e67efb4 e-con-full e-flex e-con e-child\" data-id=\"e67efb4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8c3276d elementor-widget elementor-widget-text-editor\" data-id=\"8c3276d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2>Oncopeptides avser att genomf\u00f6ra en riktad nyemission<\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-52565e9 elementor-widget elementor-widget-text-editor\" data-id=\"52565e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>21 mars 2018 \u2013 Regulatoriskt pressmeddelande<\/p><p>Oncopeptides AB offentligg\u00f6r idag avsikten att genomf\u00f6ra en riktad nyemission till svenska och internationella institutionella investerare (\u201cNyemissionen\u201d). Bolaget har anlitat ABG Sundal Collier AB, Carnegie Investment Bank AB (publ), DNB Markets, en del av DNB Bank ASA, och Jefferies International Limited som Joint Bookrunners (\u201dJoint Bookrunners\u201d) i Nyemissionen. Bookbuilding-f\u00f6rfarandet kommer att p\u00e5b\u00f6rjas omedelbart.   <\/p><p>Teckningskursen i Nyemissionen och antalet nyemitterande aktier kommer att fastst\u00e4llas genom ett accelererat bookbuilding-f\u00f6rfarande. Antalet nyemitterade aktier kommer dock inte att \u00f6verstiga 10 procent av antalet utest\u00e5ende aktier i Bolaget (d.v.s. uppg\u00e5 till h\u00f6gst 3 980 000 aktier).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6ae9794 elementor-widget elementor-widget-button\" data-id=\"6ae9794\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-avser-att-genomfora-en-riktad-nyemission\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">L\u00e4s pressmeddelandet<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"featured_media":0,"parent":5698,"menu_order":0,"template":"","meta":{"_acf_changed":false},"protected-content":[341],"class_list":["post-6926","investors","type-investors","status-publish","hentry","protected-content-show-disclaimer"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/investors"}],"version-history":[{"count":1,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6926\/revisions"}],"predecessor-version":[{"id":6927,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/6926\/revisions\/6927"}],"up":[{"embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/investors\/5698"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=6926"}],"wp:term":[{"taxonomy":"protected-content","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/protected-content?post=6926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}